Evidence map›Paper›PMID 31775675›Full record

ArticleBMC cancer2019

Dual time point

Yoji Yamagishi, Tomomi Koiwai, Tamio Yamasaki, Takahiro Einama, Makiko Fukumura, Miyuki Hiratsuka, Takako Kono, Katsumi Hayashi, Jiro Ishida, Hideki Ueno and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Dual-time-point [EJNMMI research · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yoji YamagishiDepartment of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Tomomi KoiwaiDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Tamio YamasakiDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Takahiro EinamaDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Makiko FukumuraDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Miyuki HiratsukaDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Takako KonoDepartment of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Katsumi HayashiDepartment of Radiology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Jiro IshidaTokorozawa PET Diagnostic Imaging Clinic, 7-5 Higashisumiyoshi, Tokorozawa, Saitama, 359-1124, Japan.
Hideki UenoDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Hitoshi TsudaDepartment of Basic Pathology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan. hstsuda@gmail.com.
National Defense Medical College · JPNational Defense Medical College Hospital · JP

Funding

Japan Society for the Promotion of Science 18K07340
6 · The paper itself

Abstract

backgroundTo evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV

methodsFour hundred and sixty-four patients with primary breast cancer underwent

resultsThe optimal cutoff values of SUV

conclusionDual time point

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedAlgorithmsBiomarkers, TumorBreast NeoplasmsDisease ProgressionFemaleHumansImage Processing, Computer-AssistedMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisRecurrenceBiomarkers, TumorFluorodeoxyglucose F18Dual time pointPrimary breast cancerΔSUVmax%

Identifiers

PMID31775675
PMCPMC6882358
OpenAlexW2989671318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.